(Q33670828)

28 July 2017

1 reference

title

Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes (English)

1 reference

28 July 2017

1 reference

Owens DR

1

1 reference

28 July 2017

publication date

1 June 1999

1 reference

European Journal of Clinical Investigation

28 July 2017

published in

1 reference

28 July 2017

volume

29 Suppl 2

1 reference

28 July 2017

page(s)

30-37

1 reference

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

Pathogenesis of non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

Epidemiological evidence for the association of hyperglycaemia and atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

Drugs on the horizon for treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

Postprandial glucose and vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

Regulation, perturbation, and correction of metabolic events in pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

Hypoglycaemic effects of the novel antidiabetic agent repaglinide in rats and dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

Repaglinide, glibenclamide and glimepiride administration to normal and hereditarily diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00005.X

10.1046/J.1365-2362.1999.00005.X

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference